HoneyNaps gets FDA clearance for AI sleep device

HoneyNaps has won U.S. Food and Drug Administration clearance for its SOMNUM V3.0 software, marking a regulatory milestone for the AI-based sleep medicine company. The FDA granted 510(k) clearance number K253390 to the device, which uses artificial intelligence to analyze polysomnography data and classify sleep-disordered breathing subtypes. This approval builds on previous clearance for the company’s SOMNUM V1.1.2 version and expands the software’s capabilities for automated analysis.

Automated Classification of Sleep Disorders

SOMNUM V3.0 functions as clinical decision support software intended to assist medical professionals. The system is designed to analyze sleep staging and detect respiratory events automatically. The new software goes beyond standard methods by detecting apnea and hypopnea events and classifying them into specific subtypes: Obstructive Sleep Apnea (OSA), Central Sleep Apnea (CSA), and Mixed Sleep Apnea (MSA). While conventional approaches often rely on composite indices to assess severity, SOMNUM V3.0 provides event-level classification intended to support more detailed clinical scoring.

By analyzing subtle physiological patterns from multi-channel biosignals, the software can distinguish between different apnea subtypes. This capability may be difficult to achieve through manual scoring alone. The system aims to assist clinicians in treatment planning by providing a more accurate assessment of sleep-disordered breathing severity. Validation results submitted to the FDA show the algorithms achieved an Overall Percent Agreement (OPA) of more than 97% across respiratory event categories. This high rate of agreement supports the software’s performance in automated event detection and classification.

The process of analyzing polysomnography data involves examining various physiological signals, such as brain waves, muscle activity, and heart rate, to identify patterns and anomalies that may indicate sleep disorders. SOMNUM V3.0’s ability to automatically detect and classify these events can help reduce the workload of medical professionals, who often spend considerable time manually reviewing and interpreting polysomnography data. By streamlining this process, the software can enable clinicians to focus on higher-level decision-making and patient care.

HoneyNaps USA President Sean Ha (Tae Kyoung Ha) said the clearance represents regulatory validation of the AI algorithm’s clinical performance. The company remains focused on advancing AI-driven sleep diagnostics through continued innovation in automated analysis and next-generation digital biomarkers. This regulatory step provides a foundation for the company’s broader plans to develop digital biomarkers for sleep apnea.

Next-Generation Digital Biomarkers

HoneyNaps is currently developing next-generation AI technologies to enable a more full evaluation of disease severity and associated health risks. The company is working on digital biomarkers including Hypoxic Burden (HB), Arousal Burden (AB), and Ventilatory Burden (VB). These tools are intended to provide deeper insights into the physiological impacts of sleep apnea beyond simple event counts. The company plans to pursue additional FDA 510(k) clearances for future versions of SOMNUM that incorporate these capabilities. This roadmap suggests a shift toward more granular monitoring of sleep health, which could eventually change how doctors track long-term respiratory issues.

The development of digital biomarkers such as HB, AB, and VB reflects a growing recognition of the need for more subtle and full assessments of sleep health. By quantifying the physiological burdens associated with sleep apnea, these biomarkers can help clinicians better understand the underlying mechanisms of the disease and develop more effective treatment strategies. Furthermore, the integration of these biomarkers into SOMNUM V3.0 and future software versions can facilitate more personalized and targeted approaches to sleep medicine, ultimately leading to improved patient outcomes.

As HoneyNaps continues to innovate and expand its capabilities in AI-driven sleep diagnostics, the company is poised to play a leading role in shaping the future of sleep medicine. With its strong foundation in automated analysis and digital biomarker development, HoneyNaps is well-positioned to address the complex and evolving needs of the sleep health community. The company’s website, www.honeynaps.com, provides additional information on its products and initiatives, offering a valuable resource for medical professionals, researchers, and individuals interested in sleep health and AI-driven diagnostics.